Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | LMNA | P02545 | 7/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.76 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.76 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.76 |
| ▸ | HTR2A | P28223 | 5/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.76 |
| ▸ | HRH1 | P35367 | 5/20 | 0.76 |
| ▸ | DRD3 | P35462 | 5/20 | 0.76 |
| ▸ | HTR2B | P41595 | 5/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.76 |
| ▸ | HTR2C | P28335 | 4/20 | 0.76 |
| ▸ | HTR1A | P08908 | 4/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perphenazine SCHEMBL1069857 | 1.00 | MAPT (0.76) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Perphenazine SCHEMBL246992 | 0.99 | MAPT (0.78) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Perphenazine SCHEMBL1069999 | 0.90 | LMNA (0.78) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| SCHEMBL21525461 | 0.90 | MAPT (0.76) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Perphenazine SCHEMBL1069230 | 0.89 | MAPT (0.76) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Perphenazine SCHEMBL1069229 | 0.89 | LMNA (0.79) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Perphenazine SCHEMBL145754 | 0.88 | MAPT (0.98) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Perphenazine SCHEMBL140891 | 0.88 | MAPT (0.98) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Perphenazine SCHEMBL29846305 | 0.88 | MAPT (0.98) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 | |
| Perphenazine SCHEMBL144029 | 0.88 | LMNA (0.75) | MAPTLMNAMAPK1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888120-B1 | NOVEL SALTS OF CONJUGATED PSYCHOTROPIC DRUGS AND PROCESSES OF PREPARING SAME | UNIV RAMOT (IL) | 2012-12-05 | — | — | EP | disclosed |
| EP-2272537-A2 | Salts of conjugated psychotropic drugs and processes of preparing same | Ramot at Tel-Aviv University Ltd. (IL) | 2011-01-12 | — | — | EP | disclosed |
| US-20090298814-A1 | Novel salts of conjugated psychotropic drugs and processes of preparing same | RAMOT AT TEL AVIV UNIVERISTY LTD (IL) | 2009-12-03 | — | — | US | disclosed |
| EP-1888120-A2 | NOVEL SALTS OF CONJUGATED PSYCHOTROPIC DRUGS AND PROCESSES OF PREPARING SAME | Ramot at Tel Aviv University Ltd. (IL) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006131923-A2 | NOVEL SALTS OF CONJUGATED PSYCHOTROPIC DRUGS AND PROCESSES OF PREPARING SAME | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298814-A1 | Novel salts of conjugated psychotropic drugs and processes of preparing same | SLC7A1, SLC6A2, SLC18A2 | DRD2 114/4885MAPT 300/4885LMNA 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.